A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II)
A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II)
The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 509 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Actual Study Start Date: March 2, 2020
Estimated Primary Completion Date: May 2022
Estimated Study Completion Date: May 2023
Arms:
- Experimental: Bimekizumab dosing regimen 1
- Experimental: Bimekizumab dosing regimen 2
- Experimental: Bimekizumab dosing regimen 3
- Placebo Comparator: Placebo Group
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Actual enrolment | 509 |
| Actual Study start date | 02 March 2020 |
| Estimated Study Completion Date | 01 May 2023 |